Brokerages Set argenx SE (NASDAQ:ARGX) Target Price at $687.00

Shares of argenx SE (NASDAQ:ARGX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-three analysts that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $687.00.

Several analysts recently issued reports on the company. HC Wainwright upped their target price on argenx from $717.00 to $720.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Oppenheimer increased their price objective on argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Piper Sandler boosted their target price on shares of argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a report on Tuesday, January 7th. JMP Securities upped their target price on shares of argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Finally, Wells Fargo & Company lifted their price target on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th.

argenx Price Performance

NASDAQ:ARGX traded down $34.95 during trading hours on Wednesday, reaching $555.11. 547,357 shares of the stock were exchanged, compared to its average volume of 297,480. argenx has a twelve month low of $352.77 and a twelve month high of $678.21. The stock has a market cap of $33.73 billion, a PE ratio of -630.81 and a beta of 0.60. The firm has a 50 day moving average of $621.43 and a 200 day moving average of $603.70.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. Equities research analysts anticipate that argenx will post 3.13 earnings per share for the current year.

Hedge Funds Weigh In On argenx

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GeoWealth Management LLC boosted its holdings in shares of argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after acquiring an additional 18 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in shares of argenx during the fourth quarter worth $37,000. Global Retirement Partners LLC grew its stake in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after purchasing an additional 48 shares during the last quarter. FIL Ltd acquired a new stake in argenx in the fourth quarter valued at $38,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in argenx during the 4th quarter worth about $38,000. Institutional investors own 60.32% of the company's stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.